

Pharmacology of Vasopressors and Inotropes

Sara Haney Shields

Rachel M. Holland

REFERENCES

1. Dargent A, Nguyen M, Fournel I, et al: Vasopressor cumulative dose requirement and risk of early death during septic shock: an analysis from the EPISS Cohort. *Shock* 49: 625, 2018. [PMID: 29040212]
2. Jentzer JC, Coons JC, Ling CB, Schmidhofer M: Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. *J Cardiovasc Pharm Ther* 20: 249, 2015.
3. Moranville MP, Mieux KD, Santayana EM: Evaluation and management of shock states: hypovolemic, distributive, and cardiogenic shock. *J Pharm Pract* 24: 44, 2011. [PMID: 21507874]
4. <http://accessmedicine.mhmedical.com/drugs.aspx>. (Access Medicine: Drug Monograph, McGraw-Hill.) Accessed May 20, 2018.
5. Rhodes A, Evans LE, Alhazzani W, et al: Surviving Sepsis Campaign. *Crit Care Med* 45: 486, 2017. [PMID: 28098591]
6. Wiggins BS, Sanoski CA: Chapter 5: vasoactive and inotropic agents, in: *Emergency Cardiovascular Pharmacotherapy: A Point-of-Care Guide*. Bethesda, MD: American Society of Health-System Pharmacists; 2012: 89-120.
7. Eschenhagen T: Chapter 29. Therapy of heart failure, in Brunton LL, Hilal-Dandan R, Knollmann BC (eds): *Goodman & Gilman's the Pharmacological Basis of Therapeutics*, 13th ed. New York, NY: McGraw-Hill; 2018.
8. Holden D, Ramich J, Timm E, et al: Safety considerations and guideline-based safe use recommendations for "bolus-dose" vasopressors in the emergency department. *Ann Emerg Med* 71: 83, 2018. [PMID: 28601272]
9. Richard JD, Saloman L, Boyer A, et al: Central or peripheral catheters for initial venous access of ICU patients: a randomized controlled trial. *Crit Care Med* 41: 2108, 2013. [PMID: 23782969]
10. Loubani OM, Grean FS: A systematic review of extravasation and local tissue injury from the administration of vasopressors through peripheral intravenous catheters and central venous catheters. *J Crit Care* 30: 653.e9, 2015. [PMID: 25669592]
11. Brewer JM, Puskarich MA, Jones AE: Can vasopressors safely be administered through peripheral intravenous catheters compared to central venous catheters. *Ann Emerg Med* 66: 629, 2015. [PMID: 26210381]
12. Cardenas-Garcia J, Schaub KF, Belchikov YG, et al: Safety of peripheral intravenous administration of vasoactive medication. *J Hosp Med* 10: 581, 2015. [PMID: 26014852]
13. Panchal AR, Satyanarayan A, Bahadir JD, et al: Efficacy of bolus-dose phenylephrine for peri-intubation hypotension. *J Emerg Med* 49: 488, 2015. [PMID: 26104846]
14. Schwartz MB, Ferreira JA, Aaronson PM: The impact of push-dose phenylephrine use on subsequent preload expansion in the ED setting. *Am J Emerg Med* 34: 2419, 2016. [PMID: 27720568]
15. Acquisto NM, Bodkin RP, Johnstone CJ: Medication errors with push dose pressors in the emergency department and intensive care units. *Am J Emerg Med* 35: 1964, 2017. [PMID: 28625533]
16. Cole JB: Bolus-dose vasopressors in the emergency department: first, do no harm; second, more evidence is needed. *Ann Emerg Med* 71: 93, 2018. [PMID: 28754354]
17. Awad NI, Swaminathan AK, Hayes BD: Medication errors with push dose pressors in the emergency department and intensive care units. *Am J Emerg Med* 36: 519, 2018. [PMID: 28789890]
18. Swenson K, Rankin S, Daconti L, et al: Safety of bolus-dose phenylephrine for hypotensive emergency department patients. *Am J Emerg Med* pii: S0735-6757(18)30109-8, 2018 [Epub ahead of print].
19. Link MS, Berkow LC, Kudenchuk PJ, et al: Part 7: Adult advanced cardiovascular life support: 2015 American Heart Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. *Circulation* 132: S444, 2015. [PMID: 26472995]
20. Product Information: Giapreza® IV, Angiotensin II. San Diego, CA: La Jolla Pharmaceutical Company; 2017.
21. Khanna A, English SW, Wang ES, et al: Angiotensin II for the treatment of vasodilatory shock. *N Eng J Med* 377: 419, 2017. [PMID: 28528561]
22. Busse LW, Wang ES, Chalikanda DM, et al: Clinical experience with IV angiotensin II administration: a systematic review of safety. *Crit Care Med* 45: 1285, 2017. [PMID: 28489648]
23. Westfall TC, Macarthur H, Westfall DP: Chapter 12. Adrenergic agonists and antagonists, in Brunton LL, Hilal-Dandan R, Knollmann BC (eds): *Goodman & Gilman's the Pharmacological Basis of Therapeutics*, 13th ed. New York, NY: McGraw-Hill; 2018.
24. Assad-Kottner C, Chen D, Jahanyar J, et al: The use of continuous milrinone therapy as bridge of transplant is safe in patients with short waiting times. *J Card Fail* 14: 839, 2008.